Evinacumab

Evinacumab

Evinacumab (pronounced as ev"i nak' ue mab) is a monoclonal antibody used for the treatment of homozygous familial hypercholesterolemia (HoFH). It is marketed under the brand name Evkeeza by Regeneron Pharmaceuticals.

Etymology

The name Evinacumab is derived from the following components: 'Ev' for Regeneron Pharmaceuticals, 'ina' for monoclonal antibody, 'cu' for cardiovascular targets, and 'mab' for mouse antibody.

Usage

Evinacumab is used in the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C). It is used in patients who have not responded adequately to other treatments, such as diet changes, or other medications like statins and ezetimibe.

Mechanism of Action

Evinacumab works by binding to and inhibiting the function of a protein called angiopoietin-like 3 (ANGPTL3). ANGPTL3 is a protein that plays a crucial role in regulating the levels of various lipids in the body. By inhibiting ANGPTL3, evinacumab reduces the levels of LDL-C in the blood.

Side Effects

Common side effects of evinacumab include nasopharyngitis, influenza, rhinitis, and dizziness. Serious side effects may include allergic reactions.

Related Terms

• Monoclonal antibody
• Homozygous familial hypercholesterolemia
• Regeneron Pharmaceuticals
• Statins
• Ezetimibe
• Angiopoietin-like 3
• Nasopharyngitis
• Influenza
• Rhinitis
• Dizziness

External links

• Medical encyclopedia article on Evinacumab
• Wikipedia's article - Evinacumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski